SEC Form SC 13D/A filed by Enochian Biosciences Inc. (Amendment)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.

See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following pages)

(1) The total number of shares represents 3,770,869 shares of common stock and 5,650,000 warrants to purchase shares of common stock owned by RS Group ApS which are immediately exercisable. Mr. Sindlev is the Chief Executive Officer and sole owner of RS Group ApS, consequently, he may be deemed the beneficial owner of the shares.

(2) The percentage reported in this Schedule 13D is based upon 13,727,538 shares of common stock outstanding according to the Annual Report on Form 10-K filed by Renovaro Biosciences Inc. (formerly known as DanDrit BioTech USA, Inc.) (the “Issuer”) on September 29, 2017, plus 5,650,000 shares of common stock of the Issuer that are issuable upon exercise of warrants owned by the Reporting Persons.

(1) The total number of shares represents 3,770,869 shares of common stock and 5,650,000 warrants to purchase shares of common stock owned by RS Group ApS which are immediately exercisable. Mr. Sindlev is the Chief Executive Officer and sole owner of RS Group ApS a, consequently, he may be deemed the beneficial owner of the shares.

(2) The percentage reported in this Schedule 13D is based upon 13,727,538 shares of common stock outstanding according to the Annual Report on Form 10-K filed by the Issuer on September 29, 2017, plus 5,650,000 shares of common stock of the Issuer that are issuable upon exercise of warrants owned by the Reporting Persons.

AMENDMENT NO. 3 SCHEDULE 13D

  This Amendment No. 3 to Schedule 13D (this “Amendment”) is filed on behalf of RS Group ApS and Rene Sindlev. Mr. Sindlev and RS Group ApS are collectively, the “Reporting Persons”. This Amendment modified the Amendment No. 2 to Schedule 13D filed by the Reporting Persons on January 24, 2024 (the “Prior 13D”).

This Amendment is being filed to report the purchase of additional securities of the Issuer by RS Group ApS. On October 13, RS Group ApS purchased 250,000 warrants to purchase shares of common stock. In addition, this Amendment is being filed to report that RS Arving ApS (an entity which Mr. Sindlev is the Chief Executive Officer and controlling shareholder) transferred all of the securities it owns of the Issuer (500,000 shares of common stock and 1,000,000 warrants to purchase shares of common stock) to RS Group ApS.

Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Prior 13D. Except as expressly amended and supplemented by this Amendment, the Prior 13D is not amended or supplemented in any respect, and the disclosures set forth in the Prior 13D, other than as amended herein are incorporated by reference herein.

Item 1. Security and Issuer

This Schedule 13D relates to the common stock, par value $0.0001 per share (the “Common Stock”) of the Renovaro Biosciences Inc. (previously known as Enochian Biosciences Inc. and at the time of the reported transaction, DanDrit BioTech USA, Inc.), whose principal executive offices are located at 2080 Century City East, Suite 906, Los Angeles, CA 90067.

Item 4. Purpose of the Transaction

Item 4 is hereby amended and modified to include the following (which shall be in addition to the information previously included in the Prior 13D):

This Amendment is being filed to report the purchase of additional securities of the Issuer by RS Group ApS. On October 13, RS Group ApS purchased 250,000 warrants to purchase shares of common stock in a private placement offering conducted by the Issuer. The warrants are immediately exercisable for $2.00 per share. In addition, this Amendment is being filed to report that RS Arving ApS (an entity which Mr. Sindlev is the Chief Executive Officer and controlling shareholder) transferred all of the securities it owns of the Issuer (500,000 shares of common stock and 1,000,000 warrants to purchase shares of common stock) to RS Group ApS.

Item 5. Interest in Securities of the Issuer

Item 5 is hereby amended and modified to include the following:

(a) and (b).

The responses of the Reporting Persons to rows 7, 8, 9, 10, 11 and 13 on the cover pages of this Statement are incorporated herein by reference. Mr. Sindlev has the sole power to direct the voting and/or disposition of the shares of Common Stock owned by RS Group ApS.

 (c) Other than as reported on the Prior 13D, the Reporting Persons have not effected any transactions in the Common Stock in the last 60 days.

Item 7. Material to be Filed as Exhibits

Exhibit 1 Joint Filing Agreement

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 24, 2024